U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07360743) titled 'Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels' on Jan. 13.
Brief Summary: Anti-PD-1 monotherapy has demonstrated significant clinical efficacy in advanced or metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression (tumor proportion score [TPS] >50%), outperforming platinum-based chemotherapy in terms of objective response rate (ORR) and overall survival (OS). Pivotal randomized trials such as KEYNOTE-024 and EMPOWER-Lung 1 established the superiority of PD-1 blockade in this patient population, leading to regulatory approvals by both the FDA and EMA for first-line treatm...